<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738786</url>
  </required_header>
  <id_info>
    <org_study_id>2020-08-012</org_study_id>
    <nct_id>NCT04738786</nct_id>
  </id_info>
  <brief_title>Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers</brief_title>
  <official_title>Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers: A Prospective Multicenter Randomized Non-inferiority Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective multicenter randomized non-inferiority clinical trial, to evaluate the efficacy&#xD;
      and safety of 1.0 cm-safety margin surgery, compared with 1.5 cm safety margin surgery for&#xD;
      cT1-2N0 oral tongue cancer&#xD;
&#xD;
      Summary:&#xD;
&#xD;
      A current standard primary treatment for oral tongue cancer is a curative surgical resection&#xD;
      with/without adjuvant radiation treatments (or chemoradiation).&#xD;
&#xD;
      In pathological analysis of surgical specimens, more than 5 mm of non-tumorous tissues from&#xD;
      the tumor border is regarded as a safe negative resection margin, according to the NCCN&#xD;
      guideline (the National Comprehensive Cancer Network, Dec 10. 2020). To achieve this clear&#xD;
      margin, surgeons are apt to use a 1.0 to 1.5 cm safety margin around the gross tumor during&#xD;
      surgery, considering 30-50% tumor shrinkage in tissue fixation process.&#xD;
&#xD;
      Many previous retrospective data have been reported to suggest the optimal or proper surgical&#xD;
      extent for oral tongue cancer. Wider resection can lead to better local control, however, it&#xD;
      sacrifices more normal tissue, resulting in the functional deficit of tongue (speech and&#xD;
      swallowing), even with reconstruction.&#xD;
&#xD;
      Unfortunately up to now, no prospective comparison of a different surgical safety margin for&#xD;
      oral tongue cancer have been conducted to draw a more solid conclusion. Particularly in early&#xD;
      stage oral tongue cancer (cT1-2N0), some study results have suggested that less than 5 mm&#xD;
      resection margin in pathology specimens can be also safe and effective in terms of tumor&#xD;
      control.&#xD;
&#xD;
      To achieve a well-grounded result about the proper surgical safety margin in early stage&#xD;
      (cT1-2N0) oral tongue cancer, we will compare the outcomes of the two (1.5 cm versus 1.0 cm)&#xD;
      surgical safety margin in curative resection for cT1-2N0 oral tongue cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization&#xD;
&#xD;
        -  The randomized allocation table was made by stratified block randomization methods with&#xD;
           1:1 ratio according to each participating surgeon and tumor stage.&#xD;
&#xD;
        -  Baseline number (BN) should be provided to the subjects in the order of the date of&#xD;
           surgery.&#xD;
&#xD;
      Surgical Procedure&#xD;
&#xD;
        -  The study includes T1-2N0 oral tongue cancer patients. For the management of the primary&#xD;
           lesion, wide resection with 1.0- or 1.5-cm surgical safety margin should be performed&#xD;
           according to the results of study allocation.&#xD;
&#xD;
        -  Neck management can be resection of primary tumor without neck dissection, with&#xD;
           ipsilateral or bilateral neck dissection (guided by tumor location) or with sentinel&#xD;
           lymph node biopsy, according to the NCCN guideline (version 1.2021).&#xD;
&#xD;
      Evaluation of the surgical safety margin&#xD;
&#xD;
        -  The surgical safety margin should be meticulously evaluated in the pathology specimens&#xD;
           in all directions.&#xD;
&#xD;
        -  The surgical margins less than 0.3 or 0.5 cm in final pathology results are considered&#xD;
           as the close surgical margin.&#xD;
&#xD;
      Adjuvant Treatment&#xD;
&#xD;
        -  The adjuvant treatments either radiotherapy or chemoradiotherapy are conducted if&#xD;
           indicated following the NCCN guideline.&#xD;
&#xD;
        -  The follow-up after completion of the definitive treatment are made following the NCCN&#xD;
           guideline.&#xD;
&#xD;
      Efficacy evaluation&#xD;
&#xD;
        -  The primary outcomes are determined with 2-year local control rates after the completion&#xD;
           of the curative treatments.&#xD;
&#xD;
        -  The secondary outcomes are determined with the 5-year disease-free survival rates and&#xD;
           speech/articulation functional analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective multicenter randomized non-inferiority clinical trial, comparing two groups; 1.5 cm surgical safety margin versus 1.0 cm surgical safety margin in curative resection for cT1-2N0 oral tongue cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year local control rate</measure>
    <time_frame>2 year</time_frame>
    <description>At 2 years after the completion of treatment, % of local control (or recurrence rate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5 year recurrence free survival</measure>
    <time_frame>5 year</time_frame>
    <description>5 year disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech function</measure>
    <time_frame>2 year</time_frame>
    <description>Articulation score A seven-point articulation score (7: Within normal limits, 6 Mild-slight distortion and imprecision of consonants only, 5: Mild to moderate-all consonants targeted, 4: Moderate- at least 2 consonants placements acoustically distant from the target, 3: Moderate to marked-consonants and vowels both affected, 2: Marked- uses adaptive compensatory articulation for all lingual consonants, 1: Severe- does not use effective compensatory articulations) Reference: An objective assessment of speech and swallowing following free flap reconstruction for oral cavity cancers. Br J Plastic Surg 1996;49:363-9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing function</measure>
    <time_frame>2 year</time_frame>
    <description>Swallowing performance status score. A seven-point swallowing performance scale (1: Normal, 2: Within functional limits, 3: Mild impairment, 4, Mild-moderate, 5, Moderate, 6: Moderate-severe, 7: Severe impairment). (Reference: Swallowing Function in Patients With Head and Neck Cancer Prior to Treatment Arch Otolaryngol Head Neck Surg. 2000;126(3):371-377.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1358</enrollment>
  <condition>Tongue Cancer</condition>
  <condition>Tongue Cancer TNM Staging Primary Tumor (T) T1</condition>
  <condition>Tongue Cancer TNM Staging Primary Tumor (T) T2</condition>
  <condition>Surgery</condition>
  <condition>Resection Margin</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Wide surgical safety margin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narrow surgical safety margin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers</intervention_name>
    <description>Surgical resection including 1.5 cm normal tissue around the gross tumors&#xD;
Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side).</description>
    <arm_group_label>Wide surgical safety margin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers</intervention_name>
    <description>Surgical resection including 1.0 cm normal tissue around the gross tumors</description>
    <arm_group_label>Narrow surgical safety margin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically proven oral tongue squamous cell carcinoma&#xD;
&#xD;
          -  Stage cT1-2N0M0 tumors&#xD;
&#xD;
          -  Treatment-na√Øve tumor&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification 1-3.&#xD;
&#xD;
          -  Patients who give a written informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cT3-4 or N(+) tumors&#xD;
&#xD;
          -  Recurrent tumors or salvage surgery&#xD;
&#xD;
          -  Patients who have had a previous head and neck surgery and radiation treatment.&#xD;
&#xD;
          -  Patients who have other head and neck cancer, within the last 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han-Sin Jeong, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head and Neck Cancer Center, Samsung Medical Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han-Sin Jeong, MD PhD</last_name>
    <phone>82-2-3410-3579</phone>
    <email>hansin.jeong@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeon-Yeob Jang, MD PhD</last_name>
    <email>manup1377@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han-Sin Jeong, MD, PhD</last_name>
      <phone>82-2-3410-3577</phone>
      <email>hansin.jeong@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Han-Sin Jeong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youngho Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eunjae Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou university School of Medicine</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeon Yeob Jang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Jang JY, Choi N, Ko YH, Chung MK, Son YI, Baek CH, Baek KH, Jeong HS. Differential Impact of Close Surgical Margin on Local Recurrence According to Primary Tumor Size in Oral Squamous Cell Carcinoma. Ann Surg Oncol. 2017 Jun;24(6):1698-1706. doi: 10.1245/s10434-016-5497-4. Epub 2016 Aug 12.</citation>
    <PMID>27519352</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Han-Sin Jeong</investigator_full_name>
    <investigator_title>Director of Head and Neck Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Tongue cancer</keyword>
  <keyword>Surgery</keyword>
  <keyword>Safety margin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tongue Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators will make our participant data available to other researchers after completion of this study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

